Holen Sie sich die Stockscreener-App
8.32
1.54%
-0.13
Handel nachbörslich:
8.29
-0.03
-0.36%
Schlusskurs vom Vortag:
$8.45
Offen:
$8.6
24-Stunden-Volumen:
576.61K
Relative Volume:
0.40
Marktkapitalisierung:
$495.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-110.66M
KGV:
-2.6871
EPS:
-3.0963
Netto-Cashflow:
$-97.76M
1W Leistung:
-5.13%
1M Leistung:
+5.18%
6M Leistung:
+167.52%
1J Leistung:
+118.95%
1-Tages-Spanne:
$8.31
$8.7498
1-Wochen-Bereich:
$7.7696
$8.9599
52-Wochen-Spanne:
$1.78
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Firmenname
Kyverna Therapeutics Inc
Sektor
Branche
Telefon
(510) 626-8331
Adresse
5980 HORTON STREET, EMERYVILLE
Vergleichen Sie KYTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
8.32 | 503.68M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-05-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-10-09 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-03 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-03-04 | Eingeleitet | JP Morgan | Overweight |
| 2024-03-04 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-03-04 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Kyverna Therapeutics Inc Aktie (KYTX) Neueste Nachrichten
Is Kyverna Therapeutics Inc. stock near bottom after declineRecovery Day Options & HOKA model picks for your routine - ulpravda.ru
What dividend safety score for Kyverna Therapeutics Inc. stock2025 Earnings Surprises & Daily Stock Momentum Reports - ulpravda.ru
How Kyverna Therapeutics Inc. stock trades before earnings2025 Biggest Moves & Weekly Stock Performance Updates - ulpravda.ru
Two-Year-Old Candid Looks To Move Autoimmune TCEs Into Phase II Development - Citeline News & Insights
What margin trends mean for Kyverna Therapeutics Inc. stockWeekly Trade Review & AI Based Buy and Sell Signals - ulpravda.ru
Will Kyverna Therapeutics Inc. stock recover faster than peersJuly 2025 Patterns & Smart Money Movement Tracker - moha.gov.vn
Kyverna Therapeutics Inc Stock Analysis and ForecastPortfolio Risk Assessment & Free Strong Return On Assets - earlytimes.in
Kyverna Therapeutics Inc trading halted, volatility trading pause - MSN
Kyverna Therapeutics price target raised to $33 from $25 at Morgan Stanley - MSN
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference - The Globe and Mail
Kyverna Therapeutics price target raised to $27 from $24 at Wells Fargo - MSN
Kyverna shares jump on strong results from SPS clinical trial - MSN
Kyverna Therapeutics (NASDAQ:KYTX) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Kyverna’s Autoimmune CAR T Bet Rides On 2025–26 Trial Readouts - Finimize
The biggest end-of-year sale in the Bay Area was for $4 billion in biotech stockSan Francisco Business Times - The Business Journals
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why - The Globe and Mail
Twin Insider Buys Signal Major Confidence in Kyverna Therapeutics - TipRanks
Kyverna Therapeutics (NASDAQ:KYTX) Major Shareholder Biopartners Opportuni Westlake Purchases 133,333 Shares - MarketBeat
Beth Seidenberg Purchases 133,333 Shares of Kyverna Therapeutics (NASDAQ:KYTX) Stock - MarketBeat
Kyverna Therapeutics director Seidenberg buys $999,997 in shares By Investing.com - Investing.com Nigeria
Westlake BioPartners buys Kyverna Therapeutics (KYTX) shares worth $999,997 By Investing.com - Investing.com Australia
Kyverna Therapeutics director Seidenberg buys $999,997 in shares - Investing.com
Westlake BioPartners buys Kyverna Therapeutics (KYTX) shares worth $999,997 - Investing.com
Kyverna Therapeutics Insider Bought Shares Worth $999,998, According to a Recent SEC Filing - marketscreener.com
William Blair Initiates Coverage of Kyverna Therapeutics (KYTX) with Outperform Recommendation - MSN
Kyverna Therapeutics (KYTX) Price Target Increased by 11.68% to 28.76 - Nasdaq
Institution Moves: What margin trends mean for Kyverna Therapeutics Inc. stockForecast Cut & Community Trade Idea Sharing - ulpravda.ru
Why Kyverna Therapeutics Inc. stock is rated strong buy2025 Market Outlook & Weekly Stock Breakout Alerts - Улправда
Kyverna Therapeutics Inc. (KYTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
EPS Watch: Is Kyverna Therapeutics Inc. stock attractive after correction2025 Momentum Check & Fast Gaining Stock Reports - Улправда
Market Leaders: What margin trends mean for Kyverna Therapeutics Inc. stockJuly 2025 Pullbacks & Accurate Buy Signal Alerts - ulpravda.ru
2 'strong buy' biotech stocks with 208% to 329% upside potential - MSN
Kyverna Therapeutics announces $100 million public offering - MSN
Is Kyverna Therapeutics Inc. stock attractive after correctionDollar Strength & Daily Stock Trend Reports - ulpravda.ru
What is the fair value of Kyverna Therapeutics Inc. stock nowMarket Volume Summary & Real-Time Market Sentiment Alerts - DonanımHaber
Will Kyverna Therapeutics Inc. stock see PE expansionQuarterly Growth Report & Fast Moving Trade Plans - DonanımHaber
Aug PostEarnings: How buybacks impact Kyverna Therapeutics Inc. stock valueJuly 2025 Highlights & High Accuracy Investment Signals - ulpravda.ru
How buybacks impact Kyverna Therapeutics Inc. stock valueJuly 2025 Snapshot & Low Risk High Win Rate Picks - ulpravda.ru
Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies (NASDAQ:KYTX) - Seeking Alpha
Kyverna Therapeutics (KYTX) Valuation After Positive KYSA-8 CAR T Data and First-in-Class Prospects - Yahoo Finance
Kyverna Therapeutics Announces $100 Million Public Offering - TipRanks
Kyverna Therapeutics Signs Underwriting Agreement With J.P. Morgan, Leerink Partners and Morgan Stanley - TradingView — Track All Markets
Kyverna Therapeutics (NASDAQ:KYTX) CTO Karen Marie Walker Sells 23,998 Shares - MarketBeat
Kyverna Therapeutics CTO Karen Marie Walker Sells Shares - TradingView — Track All Markets
Officer Walker Sells 23,998 ($292.8K) Of Kyverna Therapeutics Inc [KYTX] - TradingView — Track All Markets
Kyverna Therapeutics Shares Drop After Public Offering - StocksToTrade
Kyverna Therapeutics stock plunges after $100 million share offering By Investing.com - Investing.com Nigeria
Finanzdaten der Kyverna Therapeutics Inc-Aktie (KYTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):